Fol­low­ing its lat­est set­back, Achillion posts some en­cour­ag­ing PoC da­ta for lead drug

Five months af­ter tak­ing a hit on its de­ci­sion to shelve a mid-stage pro­gram for their lead ther­a­py as a monother­a­py for parox­ys­mal noc­tur­nal he­mo­glo­bin­uria …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER